



**Errik B. Anderson D'00 T'07
Biography**

Errik Anderson is a founding member of Adimab, a privately held company, and current serves as Vice President of Operations & Finance. Adimab is changing the discovery, maturation and production of fully human therapeutic antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab rapidly selects high affinity human antibodies with improved formulation and manufacturing characteristics. Their proprietary library design and presentation technologies enable the discovery of full-length human antibodies with broad epitope coverage and high affinity - faster than any known technology platform. Adimab was founded by two of the world's leading yeast biotechnologists: Professor Tillman Gerngross (Dartmouth, Co-founder of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) who led the humanization effort to engineer yeast for the production of human glycoproteins, and Professor Dane Wittrup (MIT, Co-founder of Biodisplay, acquired by Abbott Labs in 2001) who pioneered yeast surface display for the discovery and maturation of antibody fragments.

Prior to Adimab, Mr. Anderson was at Lehman Brothers Venture Capital in New York City and in 2003 was the founding President of a small venture capital consulting and investment partnership, Seven West Ventures. Errik pursued graduate studies in bioengineering at the Thayer School of Engineering, received his MBA from the Tuck School of Business at Dartmouth College and his A.B. in Economics from Dartmouth College.